Innate Pharma (FRA:IDDA) EBIT per Share : €-0.09 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Innate Pharma EBIT per Share?

Innate Pharma's EBIT per Share for the six months ended in Dec. 2023 was €-0.12. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Innate Pharma's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Innate Pharma was 46.80% per year. The lowest was -44.60% per year. And the median was -9.40% per year.

FRA:IDDA's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Innate Pharma's EBIT for the six months ended in Dec. 2023 was €-9.61 Mil.

Innate Pharma EBIT per Share Historical Data

The historical data trend for Innate Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma EBIT per Share Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.12

-0.01

-0.57

-0.72

-0.09

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.35	0.16	-0.88	0.03	-0.12

Innate Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Innate Pharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.93	/	80.453
=	-0.09

Innate Pharma's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.614	/	80.587
=	-0.12

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.09

Innate Pharma (FRA:IDDA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Innate Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Innate Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (FRA:IDDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDDA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IPH:France

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (FRA:IDDA) Headlines

No Headlines